News

Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?

  • Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
    03/28/2024

Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why

  • Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
    03/25/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Lyra Therapeutics, Inc. (LYRA) can sell. Click on Rating Page for detail.

The price of Lyra Therapeutics, Inc. (LYRA) is 5.28 and it was updated on 2024-04-12 13:00:32.

Currently Lyra Therapeutics, Inc. (LYRA) is in undervalued.

News
    
News

Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?

  • The consensus price target hints at a 101.8% upside potential for Lyra Therapeutics (LYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
    Fri, Mar. 22, 2024

Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going

  • Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
    Fri, Mar. 08, 2024

5 Small Drug Stocks to Buy From a Rebounding Industry

  • Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
    Thu, Feb. 29, 2024

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

  • Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
    Mon, Feb. 26, 2024

What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'

  • Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
    Wed, Jan. 17, 2024
SEC Filings
SEC Filings

Lyra Therapeutics, Inc. (LYRA) - S-8

  • SEC Filings
  • 03/22/2024

Lyra Therapeutics, Inc. (LYRA) - S-3

  • SEC Filings
  • 03/22/2024

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 03/20/2024

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 02/01/2024

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 11/13/2023

Lyra Therapeutics, Inc. (LYRA) - 4/A

  • SEC Filings
  • 07/12/2023

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 07/05/2023

Lyra Therapeutics, Inc. (LYRA) - S-3

  • SEC Filings
  • 06/28/2023

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 06/26/2023

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 06/09/2023

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 06/02/2023

Lyra Therapeutics, Inc. (LYRA) - S-8

  • SEC Filings
  • 03/29/2023

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 02/28/2023

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 02/28/2023

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 02/02/2023

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 07/12/2022

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 07/12/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 06/21/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 06/13/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 05/17/2022

Lyra Therapeutics, Inc. (LYRA) - S-3

  • SEC Filings
  • 05/11/2022

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 04/26/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 04/14/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 04/13/2022

Lyra Therapeutics, Inc. (LYRA) - S-8

  • SEC Filings
  • 03/09/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 03/08/2022

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 03/08/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 02/18/2022

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 02/18/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 02/15/2022

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 09/15/2021

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 09/15/2021

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 06/22/2021

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 05/28/2021

Lyra Therapeutics, Inc. (LYRA) - S-3

  • SEC Filings
  • 05/11/2021

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 02/10/2021

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 12/17/2020

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 10/29/2020

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 10/29/2020

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 08/05/2020

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 08/05/2020

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 06/26/2020

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 06/26/2020

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 05/29/2020

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 05/15/2020

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 05/15/2020

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 05/06/2020

Lyra Therapeutics, Inc. (LYRA) - S-8

  • SEC Filings
  • 05/01/2020

Lyra Therapeutics, Inc. (LYRA) - 4

  • SEC Filings
  • 05/01/2020

Lyra Therapeutics, Inc. (LYRA) - CERT

  • SEC Filings
  • 04/30/2020

Lyra Therapeutics, Inc. (LYRA) - 3

  • SEC Filings
  • 04/30/2020

Lyra Therapeutics, Inc. (LYRA) - S-1

  • SEC Filings
  • 03/06/2020

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 01/27/2020

Lyra Therapeutics, Inc. (LYRA) - DRS

  • SEC Filings
  • 11/08/2019

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 11/28/2016

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 04/12/2013

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 10/30/2012

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 11/08/2011

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 09/08/2011

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 08/12/2010

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 05/18/2010

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 03/19/2010

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 01/20/2010

Lyra Therapeutics, Inc. (LYRA) - D

  • SEC Filings
  • 04/14/2009
Press Releases
StockPrice Release
More Headlines
News

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

  • Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
  • 12/20/2023

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

  • Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
  • 12/11/2023

Lyra Therapeutics: Hold For Phase 3 Topline

  • Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show promising efficacy data, with LYR-210 in phase 3 trials and LYR-220 in phase 2 trials. Lyra has a market cap of $190mn and enough cash to sustain operations until 2025, but more cash would be desirable.
  • 10/10/2023

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

  • Lyra Therapeutics' LYR-220 shows promise in addressing chronic rhinosinusitis, targeting a patient demographic that doesn't respond to current treatments. The company maintains a stable balance sheet with a 24-month cash runway and a healthy asset-to-liability ratio. The upcoming ENLIGHTEN 1 Phase 3 trial could significantly impact the company's clinical and financial trajectory.
  • 10/09/2023

Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up

  • Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.
  • 09/13/2023

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

  • WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the William Blair Virtual Biotechnology Conference, “Transitioning Biotech Breakthroughs to Commercial Success,” on Tuesday, July 18, 2023 from 10:00 – 10:45 a.m. ET.
  • 07/13/2023

Lyra Therapeutics Extends Gains After Insider Transactions Disclosures

  • Friday's impressive 13% surge in the shares of Lyra Therapeutics (US:LYRA) carried over into the new week as investors pushed the LYRA stock price up a further 8.6% on Monday.
  • 06/05/2023

Lyra Therapeutics to Present at Jefferies Healthcare Conference

  • WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023, at 10:30 a.m. ET.
  • 06/02/2023

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates

  • Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.
  • 05/12/2023

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

  • WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 4:35 p.m. PT.
  • 05/09/2023

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

  • WATERTOWN, Mass. , Aug. 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the company will present additional Phase 2 results from the LANTERN study for LYR‑210, the company's lead product candidate for chronic rhinosinusitis, at the 68th Annual Meeting of the American Rhinologic Society (ARS), taking place September 9-10, 2022 in Philadelphia.
  • 08/29/2022

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates

  • Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 08/09/2022

Lyra Therapeutics to Present at Upcoming Investor Conferences

  • WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D.
  • 05/26/2022

Lyra Therapeutics: Progress In The Clinic

  • Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile.
  • 05/18/2022

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates

  • Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 05/10/2022

7 Stocks to Watch for Major Insider Trading Clues

  • These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared first on InvestorPlace.
  • 04/27/2022

Lyra Therapeutics Stock Surges On Equity Raise Of $100M

  • Lyra Therapeutics Inc (NASDAQ: LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to purchase an aggregate of 5 million shares with an exercise price of $0.001 per share,.
  • 04/08/2022

Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients

  • Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients. LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages.
  • 01/24/2022

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

  • WATERTOWN, Mass., Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D.
  • 11/11/2021

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call Transcript

  • Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call Transcript
  • 11/09/2021

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society

  • WATERTOWN, Mass., Oct. 4, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, announced that new, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study, were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society (ARS) on October 1-2.
  • 10/04/2021

Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

  • LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis Patients
  • 09/21/2021

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

  • Results demonstrate XTreo™ technology platform provides targeted and sustained dosing of anti-inflammatory medication
  • 09/09/2021

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  • WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET.
  • 09/07/2021

New Strong Sell Stocks for August 20th

  • ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
  • 08/20/2021

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

  • WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m. ET.
  • 08/17/2021

New Strong Sell Stocks for August 12th

  • WKHS, SPCE, PASG, LYRA, and GO have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2021
  • 08/12/2021

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2021 Results - Earnings Call Transcript

  • Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2021 Results - Earnings Call Transcript
  • 08/09/2021

Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference

  • WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 10:00 a.m. ET. A live webcast of the fireside chat presentation will be available in the Investor Relations section of the Company's website at https://investors.lyratherapeutics.com. The webcast replay will be available for 30 days following the event.
  • 07/12/2021

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

  • -- Results Support 505(b)(2) NDA Pathway for LYR-210
  • 06/30/2021

Lyra Therapeutics Stock Is Trading Higher After Positive FDA Meeting Outcome For Rhinosinusitis Program

  • Lyra Therapeutics Inc (NASDAQ: LYRA) announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the FDA for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis (CRS). Lyra and the FDA established key elements of the Phase 3 program.
  • 06/09/2021

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

  • WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis (CRS). L
  • 06/08/2021

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q1 2021 Results - Earnings Call Transcript

  • Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q1 2021 Results - Earnings Call Transcript
  • 05/11/2021

Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

  • WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
  • 04/11/2021

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q4 2020 Results - Earnings Call Transcript

  • Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q4 2020 Results - Earnings Call Transcript
  • 03/09/2021

Why Earnings Season Could Be Great for Lyra Therapeutics (LYRA)

  • Lyra Therapeutics (LYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
  • 03/01/2021

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

  • LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
  • 01/15/2021

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

  • LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
  • 01/13/2021

6 Reasons Not To Invest In Harvest Capital (NASDAQ:HCAP)

  • Harvest Capital's portfolio is in shambles, as its portfolio companies alternate in and out of default, receiving cash injections, refinancing and credit amendments.
  • 10/16/2020

NHS 111 call centre was unsafe, says worker who nearly died from Covid

  • Stephen Poore, who spent 42 days on ventilator, says there was no social distancing at Ashford office
  • 10/12/2020

Nurses barred from NHS 111 Covid clinical division after 60% of calls unsafe

  • Concern grows over 111 guidance after audit of clinical calls handled by nurses, paramedics and physios
  • 10/01/2020

Reviewing Lyra Therapeutics (NASDAQ:LYRA) & Antares Pharma (NASDAQ:ATRS)

  • Lyra Therapeutics (NASDAQ:LYRA) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Analyst Recommendations This is a summary of current ratings and price targets for Lyra Therapeutics […]
  • 08/11/2020

New SEC Disclosure: What Should You Do With The Form CRS That Just Came In The Mail?

  • The SEC proposed this document to make life easier for investors to understand services and compare firms — and I believe it will. Let me tell you why.
  • 08/06/2020

Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  • \- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - \- Conference call and webcast today at 4:30 p.m. ET -WATERTOWN, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today reported financial results for the quarter ended June 30, 2020 and provided a corporate update.Key Second Quarter 2020 and Subsequent Highlights * Appointed Pamela Nelson Senior Vice President of Regulatory Affairs. In August, Lyra announced the appointment of Pamela Nelson to the position of Senior Vice President of Regulatory Affairs. Ms. Nelson brings with her more than 25 years of experience in the biotechnology industry, with regulatory expertise in drugs and drug/device combination products across a range of therapeutic areas from early development through to commercialization.   * Appointed Robert Richard Senior Vice President of Research and Development. In July, the company announced the appointment of Robert Richard, Ph.D., to the position of Senior Vice President of Research and Development. Dr. Richard is an industry veteran who possesses extensive leadership, product development, and commercialization experience in drug delivery and complex combination products. He will oversee the development of Lyra’s two product candidates for the treatment of chronic rhinosinusitis, including the transfer of manufacturing to the contract manufacturer, and efforts on platform.   * Closed Initial Public Offering (IPO) and Exercise in Full of Underwriters’ Option to Purchase Additional Shares. In May, Lyra announced the closing of its initial public offering of 4,025,000 shares of common stock at a public offering price of $16.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 525,000 additional shares. The gross proceeds to Lyra, before underwriting discounts, commissions, fees and expenses, were approximately $64 million.“Lyra’s second quarter IPO has placed the company in a position of strength. We expect to report topline Phase 2 results from our study of LYR-210, our lead product candidate, in chronic rhinosinusitis, in the fourth quarter of 2020,” said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics. “We have also recently strengthened our management team with some key hires, which underscore our ongoing efforts to create further shareholder value by delivering on our existing drug candidates and expanding our development pipeline.”Financial HighlightsCash and cash equivalents as of June 30, 2020 were $86.6 million, compared with $35.2 million as of March 31, 2020. The increase is attributable to proceeds received from Lyra’s IPO, which occurred during the second quarter.Research and development expenses for the quarter ended June 30, 2020 were $2.1 million compared to $3.4 million for the same period in 2019. This decrease was driven primarily by the different stages for the Phase 1 and Phase 2 clinical trials of LYR-210.General and administrative expenses for the second quarter 2020 were $2.4 million compared to $0.9 million for the same period in 2019. This increase was driven primarily by additional headcount and expenses associated with our operating as a public company.Total operating expenses for the quarter ended June 30, 2020 were $4.5 million compared to $4.3 million for the same period in 2019.Net loss for the second quarter was $4.5 million compared to $4.2 million for the same period in 2019.Conference CallIndividuals interested in listening to the conference call may do so by dialing (833) 519-1249  for domestic callers, or (914) 800-3822  for international callers, and using the conference ID: 5256524; or from the webcast link in the investor relations section of the company’s website at: www.lyratherapeutics.com. The recorded webcast will be available for replay for approximately 30 days following the call.About Lyra Therapeutics, Inc. Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company’s existing product candidates, including anticipated topline Phase 2 results from the company’s study of LYR-210, its lead product candidate, in chronic rhinosinusitis, and product development efforts.    These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company’s need for additional funding, which may not be available; the company’s limited operating history; the fact that the company has no approved products; the fact that the company’s product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company’s product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company’s product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company’s inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company’s product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company’s reliance on third parties to conduct its preclinical studies and clinical trials; the company’s inability to succeed in establishing and maintaining collaborative relationships; the company’s reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company’s intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company’s growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company’s business and operations, including the company’s clinical trials; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation.  These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the SEC on May 28, 2020 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.
  • 08/05/2020

The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings

  • Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
  • 08/05/2020

Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference

  • WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 12:30 p.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.lyratherapeutics.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.About Lyra TherapeuticsLyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company’s product development efforts and the advancement, application and efficacy of our proprietary XTreo™ platform. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company’s need for additional funding, which may not be available; the company’s limited operating history; the fact that the company has no approved products; the fact that the company’s product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company’s product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company’s product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company’s inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company’s product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company’s reliance on third parties to conduct its preclinical studies and clinical trials; the company’s inability to succeed in establishing and maintaining collaborative relationships; the company’s reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company’s intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company’s growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company’s business and operations, including the company’s clinical trials; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the SEC on May 28, 2020 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.Investor Contact: Laurence Watts619-916-7620laurence@gilmartinir.comMedia Contact:Kathryn Morris914-204-6412kathryn@theyatesnetwork.com
  • 08/04/2020

Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs

  • WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced the appointment of Pamela Nelson to the position of Senior Vice President of Regulatory Affairs. Pamela brings with her more than 25 years of experience in the biotechnology industry, with regulatory expertise in drugs and drug/device combination products across a range of therapeutic areas.“I am excited to welcome Pamela to Lyra Therapeutics, where she will play an important role in helping us obtain regulatory approval for our late stage chronic rhinosinusitis drug candidates,” said Maria Palasis, Ph.D., President and CEO of Lyra Therapeutics. “Her experience in regulatory affairs involving both drug and drug/device combinations makes her especially suited for Lyra as we advance our late stage CRS programs and broaden our pipeline into new indications.”“I am delighted to be joining Lyra. I believe the company has not only assembled a strong development pipeline, but also the right people to move drugs candidates through clinical trials, to regulatory approval, and finally into commercialization,” said Pamela Nelson, Senior Vice President of Regulatory Affairs at Lyra Therapeutics. “I look forward to working with the Lyra team and helping to bring a range of much needed therapeutics to the patients who need them.”Before joining Lyra, Pamela served as Vice President, Regulatory Affairs at Avedro, where she successfully led the company’s regulatory efforts for its first drug/device combination product from development, through FDA approval, and into commercial launch. Previously, she held regulatory positions at Alnara Pharmaceuticals, Altus Pharmaceuticals, Alkermes and Genzyme. Ms. Nelson holds a bachelor’s degree in english and a master’s degree in education administration from the University of Massachusetts at Amherst.About Lyra TherapeuticsLyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company’s product development efforts and the advancement, application and efficacy of our proprietary XTreo™ platform. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company’s need for additional funding, which may not be available; the company’s limited operating history; the fact that the company has no approved products; the fact that the company’s product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company’s product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company’s product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company’s inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company’s product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company’s reliance on third parties to conduct its preclinical studies and clinical trials; the company’s inability to succeed in establishing and maintaining collaborative relationships; the company’s reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company’s intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company’s growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company’s business and operations, including the company’s clinical trials; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the SEC on May 28, 2020 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.Investor Contact:Laurence Watts619-916-7620laurence@gilmartinir.comMedia Contact:Kathryn Morris914-204-6412kathryn@theyatesnetwork.com
  • 08/04/2020

We're Hopeful That Lyra Therapeutics (NASDAQ:LYRA) Will Use Its Cash Wisely

  • We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
  • 08/03/2020

The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings

  • Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...
  • 08/02/2020

Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference

  • WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, August 6, 2020 at 10:00 a.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.lyratherapeutics.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.About Lyra TherapeuticsLyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company’s product development efforts and the advancement, application and efficacy of our proprietary XTreo™ platform. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company’s need for additional funding, which may not be available; the company’s limited operating history; the fact that the company has no approved products; the fact that the company’s product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company’s product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company’s product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company’s inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company’s product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company’s reliance on third parties to conduct its preclinical studies and clinical trials; the company’s inability to succeed in establishing and maintaining collaborative relationships; the company’s reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company’s intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company’s growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company’s business and operations, including the company’s clinical trials; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation.  These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the SEC on May 28, 2020 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.Investor Contact: Laurence Watts 619-916-7620 laurence@gilmartinir.comMedia Contact: Kathryn Morris 914-204-6412 kathryn@theyatesnetwork.com
  • 07/30/2020

Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update

  • WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced the company will release second quarter 2020 financial results on Wednesday, August 5, 2020 after the close of market. Lyra will host a corresponding conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Conference Call and Webcast DetailsTo access the live call by phone, dial (833) 519-1249 (domestic) or (914) 800-3822 (international) and use the conference ID: 5256524. To access a live webcast of the call, please visit the Investor Relations section of the Lyra Therapeutics website at www.lyratherapeutics.com. The recorded webcast will be available for replay for approximately 30 days following the call.About Lyra Therapeutics, Inc. Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company’s product development efforts and the advancement, application and efficacy of our proprietary XTreo™ platform. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company’s need for additional funding, which may not be available; the company’s limited operating history; the fact that the company has no approved products; the fact that the company’s product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company’s product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company’s product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company’s inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company’s product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company’s reliance on third parties to conduct its preclinical studies and clinical trials; the company’s inability to succeed in establishing and maintaining collaborative relationships; the company’s reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company’s intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company’s growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company’s business and operations, including the company’s clinical trials; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation.  These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the SEC on May 28, 2020 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.Media Contact: Kathryn Morris 914-204-6412 kathryn@theyatesnetwork.comInvestor Contact: Laurence Watts 619-916-7620 laurence@gilmartinir.com
  • 07/24/2020

Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development

  • Lyra Therapeutics, Inc. (LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced the appointment of Robert Richard, Ph.D., to the position of Senior Vice President of Research and Development. Dr. Richard will oversee development for Lyra’s two product candidates for the treatment of chronic rhinosinusitis, and lead efforts on platform expansion, including next generation technologies that support new indications.
  • 07/07/2020

Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index

  • Lyra Therapeutics, Inc. (LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that the company is set to join the small cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of this year’s reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 29, 2020, according to a preliminary list of additions posted June 5, 2020. “We are pleased that Lyra will be included in the Russell 2000® and 3000® indexes, and we believe this will increase the overall awareness of, and exposure to, our stock among the investment community,” said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics.
  • 06/25/2020

Lyra Therapeutics, e.l.f. Beauty, and Avid Tech See Activist Action

  • Impactive Capital increased its stake in Avid Technology, a maker of digital-media platforms including Pro Tools. Marathon Partners disclosed a large stake in cosmetics retailer e.l.f. Beauty.
  • 06/05/2020

Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

  • WATERTOWN, Mass., May 28, 2020 -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel.
  • 05/28/2020

Lyra Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

  • Lyra Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference
  • 05/28/2020

Lyra Therapeutics to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference

  • Lyra Therapeutics to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference
  • 05/09/2020

Bigger Navy Frigates Risk Oversized $1.4 Billion Cost Per Ship

  • An artist rendering of the guided-missile frigate FFG(X).U.S. Navy graphic/Released By Tony Capaccio (Bloomberg) — The Navy truncated orders for its ill-fated Littoral Combat Ship because the…
  • 05/07/2020

Lyra Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

  • Lyra Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
  • 05/05/2020

Lyra Therapeutics Brings a Hint of Stock Market Normalcy in IPO Debut

  • When a raging bull market dies and turns into a bear market with a deep recession in less than 45 days, things are not normal. The same is true when the stock market recovers about two-thirds of its losses in 5 weeks. It has been a wild ride in 2020 and most investment banking firms […]
  • 05/01/2020

Is your FX brokerage going to be caught by CRS rulings? A Detailed insight - FinanceFeeds

  • Australia, one of the countries that is subject to the CRS, is a very well recognized center for the FX industry. Prior to July 1 this year, OTC derivatives brokers will need to determine whether they are caught by the CRS requirements. TRAction FinTech Director Sophie Gerber investigates
  • 06/08/2017
Unlock
LYRA Ratings Summary
LYRA Quant Ranking